Detalles de la búsqueda
1.
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients.
Eur Respir J
; 57(6)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33334936
2.
A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference.
COPD
; 15(1): 46-50, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29227727
3.
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Pulm Pharmacol Ther
; 29(1): 49-57, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25020273
4.
ELLIPTA Dry Powder Versus Metered-Dose Inhalers in an Optimized Clinical Trial Setting.
J Allergy Clin Immunol Pract
; 7(6): 1843-1849, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30836228
5.
A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
Int J Chron Obstruct Pulmon Dis
; 13: 2515-2523, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30174421
6.
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
Int J Chron Obstruct Pulmon Dis
; 10: 15-23, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25565796
7.
Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
J Aerosol Med Pulm Drug Deliv
; 28(6): 486-97, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26372467
8.
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Clin Ther
; 36(7): 1016-1027.e2, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947493
9.
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
Int J Chron Obstruct Pulmon Dis
; 8: 159-67, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23569370
10.
Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
Clin Drug Investig
; 33(9): 653-64, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23881566
11.
Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies.
Eur J Pharmacol
; 701(1-3): 40-8, 2013 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23276660
12.
Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
Clin Drug Investig
; 33(7): 477-88, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23784369
13.
Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
PLoS One
; 7(12): e50716, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23284643
14.
Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation.
Eur J Immunol
; 37(5): 1254-65, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17407191
15.
Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement.
Blood
; 99(7): 2477-82, 2002 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11895782
Resultados
1 -
15
de 15
1
Próxima >
>>